3 Stocks Showing Bullish Signals: CollPlant Biotechnologies (CLGN), ABVC BioPharma (ABVC), Cardiol Therapeutics (CRDL)

Biotechnology stocks continue to experience heightened volatility as investors balance near-term market pressure against longer-term clinical and regulatory opportunities. Despite broader uncertainty across small-cap healthcare equities, companies advancing innovative therapies in cardiovascular disease, oncology, and critical care remain firmly on investor watchlists heading deeper into 2026.

CollPlant Biotechnologies Ltd (CLGN)

CollPlant Biotechnologies Ltd (NASDAQ: CLGN) opened trading on May 13, 2026, with great promise as it jumped 3.38% to $0.42. During the day, the stock rose to $0.42 and sank to $0.38. Taking a long-term approach, CLGN posted a 52-week range of $0.27-$4.98.

The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 2.35%. Meanwhile, its Annual Earning per share during the time were -2.35%.  This publicly-traded company’s shares outstanding now amount to $12.80 million, simultaneously with a float of $10.34 million. The organization now has a market capitalization of $6.04 million.

ABVC BioPharma Inc (ABVC)

ABVC BioPharma Inc (NASDAQ: ABVC) started the day on May 13, 2026, with a price increase of 1.90% at $1.07. During the day, the stock rose to $1.09 and sank to $1.05. Taking a more long-term approach, ABVC posted a 52-week range of $0.88-$5.48.

It was noted that the giant of the Healthcare sector posted annual sales growth of 39.78% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 39.78%.  This publicly-traded company’s shares outstanding now amount to $25.05 million, simultaneously with a float of $20.61 million. The organization now has a market capitalization of $27.22 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to broaden its long-term growth strategy through the development of additional cardiovascular therapies aimed at larger market opportunities. By expanding beyond recurrent pericarditis, the company is positioning itself to address chronic cardiac diseases where inflammation and fibrosis play a major role in disease progression.

Market Momentum

As of May 13, 2026, CRDL closed at $1.36, up 0.74%, with trading volume of 504,589 shares compared to an average volume of 686,598 shares. The company currently maintains a market capitalization of $151.885M and a beta of 0.43, reflecting relatively moderate volatility for a small-cap biotech company. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.38 implies substantial upside potential tied to future pipeline advancement.

Pipeline Development: CRD-38

Cardiol is advancing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience while expanding applicability into broader cardiovascular indications, including heart failure. The therapy is intended to target inflammation and fibrosis, biological mechanisms strongly associated with worsening cardiac function and progressive heart disease.

Large Market Potential

Heart failure remains one of the largest cardiovascular markets globally, affecting millions of patients and generating significant healthcare costs annually. Despite the availability of multiple therapies, substantial unmet need persists for treatments capable of directly addressing inflammatory and fibrotic pathways linked to disease progression and long-term cardiac decline.

Outlook

As CRD-38 advances toward future clinical development, the program could emerge as an important secondary value driver for Cardiol. Continued progress across the broader pipeline may strengthen the company’s strategic positioning within cardiovascular biotechnology.